<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02197026</url>
  </required_header>
  <id_info>
    <org_study_id>1139.4</org_study_id>
    <nct_id>NCT02197026</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Synvisc® Versus Usual Treatments in Patients With Knee Osteoarthritis</brief_title>
  <official_title>A Multicentre, Open-label and Randomized Clinical Trial to Compare in Patient With Knee Osteoarthritis the Medicoeconomic Benefits as Well as Effectiveness and Safety of Synvisc® Versus Usual Treatments.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Comparison of treatment cost of knee osteoarthritis (OA) in patients treated with Synvisc®
      versus usual treatments as well as evaluation of safety and effectiveness of these
      treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <primary_completion_date type="Actual">February 2000</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cost of knee OA treatment including cost of side effect related to OA treatment</measure>
    <time_frame>up to 274 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) Lequesne index</measure>
    <time_frame>Day 1, 29, 91, 182 and 274</time_frame>
    <description>Index of severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Western Ontario and McMaster Universities (WOMAC) index by patient</measure>
    <time_frame>Day 1, 91, 182 and 274</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's assessment of pain on movement and rest on a visual analogue scale (VAS) through WOMAC question 1 and 3</measure>
    <time_frame>Day 1, 91, 182 and 274</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity assessment by patient and investigator on a VAS</measure>
    <time_frame>Day 1, 29, 91, 182 and 274</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute congestive OA flares assessed through a questionnaire</measure>
    <time_frame>Day 1, 29, 91, 182 and 274</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of state of health of the patients with a quality of life questionnaire (SF 12)</measure>
    <time_frame>Day 1, 91, 182, 274</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of efficacy by patient and investigator on a four-point verbal rating scale (VRS)</measure>
    <time_frame>Day 274</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of tolerability by patient and investigator on a four-point VRS</measure>
    <time_frame>Day 274</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and intensity of adverse events</measure>
    <time_frame>up to day 274</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of withdrawals due to adverse event</measure>
    <time_frame>up to day 274</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">518</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Synvisc group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of Synvisc® at day 1, day 8 and day 15; in the mean time it will be recommended to decrease or stop all other OA treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteoarthritis standard treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment will be left to the discretion of the investigator who could prescribe any therapies, except viscosupplementation product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hylan G-F 20</intervention_name>
    <arm_group_label>Synvisc group</arm_group_label>
    <other_name>Synvisc®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>Standard drug treatment at the discretion of the investigator</description>
    <arm_group_label>Osteoarthritis standard treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physiotherapy</intervention_name>
    <arm_group_label>Osteoarthritis standard treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hydrotherapy</intervention_name>
    <arm_group_label>Osteoarthritis standard treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatient aged at least 18 years

          -  Patient suffering from predominant femoro-tibial knee osteoarthrosis with or without
             effusion. The diagnosis must be based on American College of Rheumatology (ACR)
             criteria. Radiological grade will be assess according to Kellgren-Lawrence scale

          -  Assessment of pain on active movement (i.e. walking) (by the patient) must be at least
             40 mm on a 100 mm VAS

          -  Patient who received at least two courses of at least ten days within the last three
             months with non-steroidal antiinflammatory drugs (NSAID) and/or who are treated
             continuously for the last two month with slow-acting anti-osteoarthritis drugs

          -  Patient's informed written consent obtained in accordance with French legislation

        Exclusion Criteria:

          -  Patient suffering from acute congestive osteoarthritis flare of the target knee (at
             the time of inclusion) which means that concomitantly to knee effusion at least 2 of
             the following criteria are present:

               -  nocturnal disturbances due to knee pain

               -  morning stiffness over 45 minutes

               -  increase of knee pain more than 50% within the last week

               -  articular reddening

               -  articular heat

          -  Intra-articular administration of hyaluronic acid in the target knee within the
             previous year

          -  Intra-articular administration of hyaluronic acid in the target knee within the three
             previous months

          -  Any other intra-articular injection in the target knee within the last 6 months

          -  Any contraindication to intra-articular injections

          -  Present or past history of infected target knee joint

          -  Previous prosthesis knee surgery, tibial osteotomy, synovectomy or synoviorthese of
             the target knee

          -  Arthroscopy, articular lavage, debridement, menisectomy of the target knee within the
             previous year

          -  Planned knee surgery within the nine following month

          -  Any other musculoskeletal disorders that can interfere with osteoarthritis diagnosis
             or the evaluation of its severity

          -  Known hypersensitivity to avian products

          -  Presence of lymphatic or venous stasis

          -  Pregnancy or breastfeeding

          -  Clinical evidence of or known severe cardiac, hepatic, renal, metabolic,
             haematological disease, mental disturbance

          -  Participation in another clinical trial during this study or during the previous month

          -  Previous participation in this trial

          -  Patient who requires help concerning shopping or house keeping

          -  Patient unable to comply with the protocol (e.g. patient unable to attend each trial
             visit or to fill the diary booklet or the quality of life questionnaire)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2014</study_first_submitted>
  <study_first_submitted_qc>July 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2014</study_first_posted>
  <last_update_submitted>July 21, 2014</last_update_submitted>
  <last_update_submitted_qc>July 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hylan</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

